Think of Nesina as a "Me Too" Similar to Januvia, Onglyza, and Trajenta

January 2015

Nesina (nes-SEE-nah, alogliptin) will compete in a crowded market of gliptins, or DPP-4 inhibitors, for type 2 diabetes.

It's a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Trajenta (linagliptin).

Continue to recommend lifestyle changes and metformin first.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology Suggest Saving Ezetimibe as an Add-On in High-Risk Patients
Interactions Watch for TMP/SMX Rxs for Patients on Potassium-Boosting Meds
Psychiatry Recommend Reducing the Trintellix Dose by Half When Used with Bupropion
Hypothyroidism Explain That Full Benefit of Levothyroxine May Take 6 Months
Diabetes Think of Nesina as a "Me Too" Similar to Januvia, Onglyza, and Trajenta
Diabetes Suggest the Shortest and Thinnest Insulin Needle Available
Eye Health Help Dry-Eye Patients Avoid Topical Vasoconstrictors
Pediatrics Use Supportive Care Instead of Meds for Bronchiolitis in Kids
Bipolar Disorder Don't Suggest Aripiprazole or Ziprasidone for Bipolar Depression
Antithrombotics Don't Recommend Newer Oral Anticoagulants for VTEs During Pregnancy
Med Administration Recommend a Different Head Position to Make Swallowing Pills Easier